Lovaltech appointed Serge Pampfer as CEO
Serge Pampfer joined the Lovaltech team as CEO on November 2, 2023. Alongside Patrick Barillot, President and co-founder of the company, he will be driving the next stages of the startup's development. Having recently secured €5.3 million in funding through the #France 2030 initiative, the company is currently in the midst of a €1.5 million fundraising campaign. This investment will enable Lovaltech to conclude the phase 1 and 2 clinical trials for its first vaccine candidate, LVT0001. This groundbreaking vaccine is the first in the world to offer complete protection against COVID-19, halting contagion and proving effective against all existing and future variants.
This key appointment is a testament to the support provided by Da Vinci Labs, the leading deep tech incubation facility in the Loire Valley region.
Serge Pampfer, a seasoned embryologist with extensive expertise in immunology, oncology, and stem cell biology, brings a wealth of experience to the company, blending academic research with leadership roles in the life sciences sector. Following a distinguished career as a research master at FNRS and a professor at the University of Louvain, Serge Pampfer transitioned into the startup world. He held pivotal positions such as Chief Scientific Advisor at Arevia GmbH, Chief Operating Advisor at Beta-Cell NV, Chief Scientific Advisor at EureKARE SAS (a specialized investment company), and CEO at WBC SA, an incubator-investor that boasts two successful IPOs and five acquisitions among its accomplishments. His arrival at Lovaltech promises to inject fresh impetus and unrivaled expertise into the life sciences sector. We eagerly anticipate collaborating with Serge Pampfer to propel Lovaltech to new heights of innovation and success.
Patrick Barillot, President and co-founder of Lovaltech
"On behalf of the entire Lovaltech team, I extend a warm welcome to Serge, who will undoubtedly enrich us with his experience and expertise as CEO. With this new addition to our leadership team, Lovaltech is ideally positioned to finalize its seed funding round. Serge will play a crucial role in achieving our shared ambition of becoming a leading player in nasal vaccination, both in France and internationally."
Serge Pampfer, CEO of Lovaltech
"Over the past few months, I have closely followed Lovaltech's progress and have been deeply impressed by the speed and efficiency with which the team has navigated the critical steps leading to the phase 1 and 2 clinical trials of their first vaccine. It is an immense privilege to now join this team and contribute to their ambition of revolutionizing infectious disease vaccination through a truly innovative deep tech approach."
Nadège Grabowski, Head of Synthetic Biology at Da Vinci Labs
"We are delighted to have facilitated Serge's recruitment within the Lovaltech company, the first startup in our incubation portfolio. Lovaltech has demonstrated its ability to secure significant public funding, and Serge's appointment comes at the right time to set in motion the private fundraising round."
About Lovaltech
Lovaltech is a deeptech startup created in January 2022 to take over from academic research at the University of Tours and INRAE. Winner of the i-Lab competition and the #France 2030 program, the company is developing new generation vaccines. These protein vaccines administered via the nasal route are capable of better protecting all populations against infectious diseases, such as COVID-19, by inducing a dual mucosal and systemic immune response, which not only protects serious forms but also to block the transmission of the virus and to be effective on all the variants.
About Da Vinci Labs
Da Vinci Labs is a research and incubation structure inspired by Leonardo da Vinci. Its interdisciplinary and humanist approach aims to respond competitively to the ecological challenges of tomorrow and to bring out the future champions of deeptech, particularly in the field of quantum technologies, artificial intelligence and synthetic biology. To do this, Da Vinci Labs participates in European collaborative research projects and is building a technological infrastructure in Touraine, which will be made available to researchers and entrepreneurs ready to take on our major societal challenges.